Black Agenda Report
Black Agenda Report
News, commentary and analysis from the black left.

  • Home
  • Africa
  • African America
  • Education
  • Environment
  • International
  • Media and Culture
  • Political Economy
  • Radio
  • US Politics
  • War and Empire

Obamacare A Bonanza For Drug Companies, A Pain For the Public
Glen Ford, BAR executive editor
18 Nov 2009
🖨️ Print Article
expensive drugs
A Black Agenda Radio commentary by Glen Ford
Click the flash player to listen to or the mic to download an audio in MP3 format.

Why are the drug barons planning a $150 million ad campaign boosting Obama's health care scheme? They've got $21 billion worth of reasons – bonus earnings from record price hikes while wheeling and dealing with the White House. Everything the president touches turns to cash – for the corporate sector.
 
Obamacare A Bonanza For Drug Companies, A Pain For the Public
A Black Agenda Radio commentary by Glen Ford
“Obama's dealmaking in the White House is nothing less than collusion with the cartel.”
President Obama is very good at talking “the language of the deal.” He made a deal with the the drug cartel this summer, ostensibly to keep drug prices down to reduce the overall cost of health care. The drug companies promised they would cut the prices they planned to charge by about $8 billion a year for the next ten years. Now an analysis for AARP shows the drug profiteers have actually raised prices by more than $10 billion in the last year, an increase of more than 9 percent and the biggest price hike in 17 years.
Good lookin' out out, Obama. Or should I say, Good job of selling out, Mr. President. The drug industry is so happy with the deal it cut with the White House, it's launching a $150 million advertising campaign to boost ObamaCare – a cheap price to pay for yet another Obama bailout of the ruling class, this time for Big Pharma.
At the same time that the industry was pushing up drug prices by 9.3 percent, the price of generic drugs declined by about 9 percent. That means the drug cartel, under cover of Obama's deal, transformed a downward trend in pharmaceutical prices into the biggest price surge since 1992.
And what else is the drug monopoly getting from the dealmaker in the White House? Thirty million new customers, served up on a platter under the banner of health care reform. This is bait-and-switch with a vengeance. When Obama is the dealmaker, “reform” translates into instant, unprecedented profits for the corporate sector. Under this administration, the words “reform” and “bailout” are virtually synonymous.
“The drug cartel, under cover of Obama's deal, transformed a downward trend in pharmaceutical prices into the biggest price surge since 1992.”
The House version of health care reform, passed on November 7th, calls for $14 billion a year in savings on drugs, but most of those savings have already been gutted by the drug industry. So what did the Democrats accomplish by deferring to the deal struck by the White House? They have made themselves look ridiculous, irrelevant.
The drug industry pulled the same trick back in 2006, when Congress expanded the Medicare subsidized drug program by tens of millions of older people. Back then, Big Pharma seized the opportunity to push prices through the roof. Now they've done it again.
If Barack Obama is not a pro-big business president, then who is? He has guaranteed the drug barons tens of millions of captive customers, shielded the industry from pesky progressives in Congress by cutting a side deal at the White House, and then allowed the corporations to reap a $21 billion boondoggle based entirely on artificially inflated prices.
Why do Americans pay so much more for pharmaceuticals than anyone else on the planet? Because the drug industry is a cartel that sets prices as it sees fit. Barack Obama's dealmaking in the White House is nothing less than collusion with the cartel.
No one questions Barack Obama's intelligence. He is clearly a brilliant man. Therefore, one can only conclude that he is part of the con game. Obama is dealing from the bottom of the deck, passing all the good cards to his corporate partners. And the people get fleeced every time.
For Black Agenda Radio, I'm Glen Ford. On the web, go to www.BlackAgendaReport.com.

BAR executive editor Glen Ford can be contacted at Glen.Ford@BlackAgendaReport.com. 

Do you need and appreciate Black Agenda Report articles? Please click on the DONATE icon, and help us out, if you can.


More Stories


  • Gerald Horne
    Black Agenda Radio with Margaret Kimberley
    Gerald Horne: African Americans & A New History of the US
    17 Jan 2025
    Dr. Gerald Horne is an author and historian who currently holds the John J. and Rebecca Moores Chair of History and African American Studies at the University of Houston. Dr. Horne is a prolific…
  • Anthony Monteiro
    Black Agenda Radio with Margaret Kimberley
    Anthony Monteiro on Trump's Inauguration and U.S. Politics
    17 Jan 2025
    Dr. Anthony Monteiro is a Duboisian scholar and founder of the Saturday Free School for Philosophy and Black Liberation. He joins us from Philadelphia to discuss the upcoming inauguration of Donald…
  • Margaret Kimberley, BAR Executive Editor and Senior Columnist
    Joe Biden's Terrible Legacy
    15 Jan 2025
    The moniker “Genocide Joe” is well deserved and one that Joe Biden can never live down, along with any other names that describe the damage he brought to the country and to the world. His legacy is…
  • Editors, The Black Agenda Review
    INTERVIEW: The Problem of Haiti is the Same as Latin America: Gerard Pierre-Charles, 1983
    15 Jan 2025
    Despite selling out Haiti, former Haitian leftist Gerard Pierre-Charles’s 1983 diagnosis of the imperialist assault on current movements still resonates today.
  • Manley greets a crowd
    Ann Garrison, BAR Contributing Editor , Riva Enteen
    Remembering Jamaica in the East/West Crossfire, Part II
    15 Jan 2025
    Both class and color barriers were broken down during the Michael Manley era, but class barriers re-emerged.
  • Load More
Subscribe
connect with us
about us
contact us